Rigel Pharmaceuticals (RIGL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Rigel Pharmaceuticals (RIGL) do?
Rigel Pharmaceuticals (RIGL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Markets targeted prescription therapies for hematologic cancers and autoimmune conditions. Sells directly to specialty pharmacies and licenses global rights to overseas healthcare partners. Develops and sells oral targeted therapies for rare blood cancers and immune disorders through specialty pharmacies. It is worth $775.61M on the market and sold $288.33M over the last year.
- Market cap
- $775.61M
- P/E ratio
- 2.7×
- Annual sales
- $288.33M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 13, 2026
Brands and businesses behind RIGL
- Tavalisse: Generates revenue as a prescription oral tablet for adult patients with chronic immune thrombocytopenia.
- Rezlidhia: Earns sales as a daily oral capsule treating specific mutated forms of acute myeloid leukemia.
- Gavreto: Produces revenue as an oral kinase inhibitor for adults with specific RET-altered lung and thyroid cancers.
RIGL’s flags, in plain English
Each flag is a number from Rigel Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Low debt
Low debt, only 2% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 89.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Capital Works Hard
Earns 69% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.
Profit with Caveats
Bottom-line profit of $307M in the 12 months to Sep 30, 2026, next to $76M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about RIGL
How big is Rigel Pharmaceuticals?
Rigel Pharmaceuticals’ market cap is $775.61M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $288.33M: what customers paid the company over the last year, before any costs.
What is RIGL’s P/E ratio?
RIGL’s P/E ratio is 2.7×. Investors pay about 2.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with RIGL?
A significant share of annual revenue depends on prescription sales from a single drug for immune thrombocytopenia. That is one risk on Rigel Pharmaceuticals’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Rigel Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. RIGL’s filings on SEC.gov. The Margin Monkey is research, not advice.
